Device Trial Radar · NCT05574361
Continued Access Study to Evaluate Performance of the Organ Recovery Systems _LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT™_CA)
Last checked: Nov 21, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
385
Actual
Start
Sep 19, 2022
Primary completion
Sep 23, 2025
Study completion Oct 23, 2026
Sponsor
- Lead sponsor
- Organ Recovery Systems, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 10, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To provide continued access for the LLT system to provide additional safety data in support of the PILOT pivotal efficacy and safety trial
Conditions
- Liver Transplantation
Interventions
Hypothermic Machine PerfusionDevice
Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Allograft Dysfunction (EAD)Time frame: 7 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Northwestern Memorial Hospital
Chicago, Illinois
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.